한국지질동맥경화학회 학술대회

This session will explore novel insights into the role of lipid toxicity and platelet signaling in the pathogenesis of atherosclerotic inflammation. Professor Ok-Nam Bae from Hanyang University, Republic of Korea, will present on how environmental toxicants such as nanoparticles and biocides disrupt lipid homeostasis and promote vascular inflammation. Professor Jun Young Hong from Yonsei University, Republic of Korea, will discuss immune-driven remodeling of lipid metabolism that induces whitening of brown adipose tissue under thermoneutral conditions, highlighting the crosstalk between immunity and energy metabolism. Professor Jin O-Uchi from University of South Florida, USA, will elucidate the functional role of the mitochondrial calcium uniporter in human platelets and its impact on platelet aggregation and thrombosis. This multidisciplinary session will offer a comprehensive view on how metabolic stress, immune dysregulation, and platelet activation converge to drive vascular pathology.

In this special session titled “Redefining Cardiovascular Care: PCSK9 Mechanisms and siRNA-Based Advances,” ICoLA 2025 brings together leading experts to explore emerging molecular and clinical insights into lipid regulation and atherosclerotic disease management. The session opens with a comprehensive exploration of PCSK9—the master regulator of LDL metabolism and a key player in vascular inflammation—highlighting its central role in atherosclerosis. The second presentation focuses on the promise of siRNA-based lipid-lowering therapies, showcasing their transformative potential for sustained LDL-C control. Finally, the session addresses novel approaches to managing familial hypercholesterolemia beyond statin therapy, offering new hope for patients with genetically driven dyslipidemia. This session integrates advances in molecular biology, therapeutic innovation, and clinical practice, paving the way for a redefined and more personalized approach to cardiovascular prevention and treatment.

Recent updates to the ASCVD risk prediction model, including the introduction of the PREVENT equation, reflect several key advances—one of which is the integration of socioeconomic factors. This shift highlights the growing recognition of social determinants as important contributors to cardiovascular risk. In this session, we will explore the multifaceted impact of socioeconomic status on ASCVD. Professor Seonghee Choi from Seoul National University Bundang Hospital, Republic of Korea, will discuss the underlying mechanisms linking socioeconomic disadvantage to cardiovascular outcomes. Professor Jongha Baek from Gyeongsang National University, Republic of Korea, will present epidemiological evidence illustrating the magnitude of this association. Finally, Professor Sadiya S. Khan from Northwestern University Feinberg School of Medicine, USA, will introduce a novel cardiovascular risk prediction model that incorporates socioeconomic variables into traditional clinical frameworks.

Symposium 13 will highlight current trends and regional advances in dyslipidemia management, shaping the future of lipid care in Asia. The session opens with an overview of the 2024 KSoLA Consensus on Secondary Dyslipidemia, presenting practical guidance on managing lipid disorders in patients with comorbid conditions. It will then shift to epidemiological and clinical insights from China and Japan, where speakers will discuss national trends, healthcare innovations, and evolving treatment strategies. This symposium provides an opportunity to understand how different healthcare systems approach dyslipidemia and to explore collaborative pathways for improving lipid management across diverse populations in the Asia-Pacific region.

Symposium 16 is titled “Defining the Optimal LDL-C Target for Prevention of Atherosclerotic Cardiovascular and Cerebrovascular Disease.” The session opens with a cardiologist’s perspective on establishing optimal LDL-C goals for secondary prevention in high-risk patients. The second presentation offers a neurologist’s insights into optimal LDL-C levels specifically for stroke prevention. Finally, an endocrinologist will review the evidence for varying LDL-C targets according to diabetes duration and discuss strategies for personalized guideline development. This symposium promises to deliver critical, evidence-based perspectives to bridge guideline recommendations with real-world clinical practice in cardiovascular and cerebrovascular disease prevention.

Macrophage immunometabolism plays a pivotal role in orchestrating inflammation and repair in cardiovascular disease. This session will highlight emerging metabolic axes governing macrophage function in cardiometabolic injury and recovery. Professor Laurent Yvan-Charvet from INSERM, France, will introduce glutamine homeostasis as a previously overlooked regulator of cardiometabolic inflammation, shedding light on its immunomodulatory roles. Professor Edward Thorp from Northwestern University, USA, will present how myeloid cell metabolism influences both the amplification and resolution of cardiac inflammation, offering insights into innate immune reprogramming. Professor Yong Sook Kim from Chonnam National University, Republic of Korea, will present the therapeutic potential of ANGPTL4 in modulating inflammation and atherosclerosis. This session offers a comprehensive overview of the immunometabolic programming of macrophages and its translational relevance in cardiovascular injury and repair.

This session provides an in-depth exploration of the paradigm shift in obesity management from treatment to prevention. Prof. Choon Young Kim (Yeungnam University, Republic of Korea) presents the anti-obesity effects of bioactive compounds from natural products, focusing on cellular signaling and metabolic regulation. Prof. Yun Kyung Cho (University of Ulsan, Republic of Korea) discusses the therapeutic potential of semaglutide in obesity and its cardiometabolic benefits. Prof. Sang-Ho Jo (Hallym University, Republic of Korea) addresses the role of tirzepatide, a dual GIP/GLP-1 receptor agonist, in obesity treatment and comprehensive metabolic care.

The Journal of Lipid and Atherosclerosis (JLA) Committee has selected five outstanding papers published over the past year for presentation in this session. The authors will share key findings from their research on lipid metabolism and cardiovascular risk. Professor Su Youn Nam explores the association between high-density lipoprotein cholesterol and hematologic malignancy risk, while Professor Mee Kyoung Kim discusses the role of kidney function in cholesterol-related cardiovascular risk in type 2 diabetes. Professors Hayato Tada and Wen-Liang Song present on the impact of lipoprotein(a) on coronary artery disease and fibrinolysis, respectively, and Professor Belen Davico addresses the role of fatty acids in childhood obesity and cardiovascular risk. This session offers timely insights into the evolving understanding of lipid-related mechanisms in cardiometabolic diseases.